ArticleCost effectiveness and resource allocation : C/E2020

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.

Herbert H Loong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.